Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure

Acta Pharmacologica Sinica

Volumn 29, Issue 7, 2008, Pages 808-814

  Yan, Jiang Tao ^a   Wang, Tao ^a   Li, Juan ^b   Xiao, Xiao ^a,b   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

High salt diet; Humant issue kallikrein; Hypertension; Recombinant adeno associated virus vector

Indexed keywords

COLLAGEN; MESSENGER RNA; PARVOVIRUS VECTOR; PLASMID DNA; POTASSIUM ION; SODIUM ION; TISSUE KALLIKREIN; KALLIKREIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE THERAPY; HIGH SODIUM INTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE KALLIKREIN GENE; HYPERTENSION; IMMUNOREACTIVITY; MALE; NONHUMAN; POTASSIUM URINE LEVEL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ADENOVIRUS; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PLASMID; SODIUM INTAKE; SPRAGUE DAWLEY RAT; URINE;

ADENOVIRIDAE; ANIMALS; BLOOD PRESSURE; COLLAGEN; GENE THERAPY; HUMANS; HYPERTENSION; KALLIKREINS; KIDNEY; MALE; PLASMIDS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM, DIETARY;

EID: 65849310615     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00815.x     Document Type: Article

References (26)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national commi ttee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560- 72.
2. Neal B, Macmahon S, Chapman N. Effects of ACE inhibitors, calcium antagnosists, and other blood-pressure-lowering drugs. Lancet 2000; 356: 1955-64.
3. Phillips MI. Gene therapy for hypertension: the preclinical data. Hypertension 2001; 38 (Part 2): 543-8.
4. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adenoassociated virus vectors in the absence of helper virus. J Virol 1998; 72: 2224-32.
5. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000; 6: 599-602.
6. Monahan PE, Samulski RJ. AAV: is clinical success in the horizon? Gene Therapy 2000; 7: 24-30.
7. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, kininases. Pharmacol Rev 1992; 44: 1- 8.
8. Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal diseases. Exp Physiol 2005; 90: 291-8.
9. Wang T, Li H, Zhao C, Chen C, Li J, Chao J, et al. Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 2004; 11: 1342-50.
10. Weinberger M. Salt sensit ivity of blood pressure in humans. Hypertension 1996; 27: 481-90.
11. Weinberger M. Salt sensitivity: does it play an important role in the pathogenesis and t reatment of hypertension? Curr Opin Nephrol Hypertens 1996; 5: 205-8.
12. Weinberger M. Salt and blood pressure. Curr Opin Cardiol 2000; 15: 254-7.
13. Weinberger M. More on the sodium saga. Hypertension 2004; 44: 609-11.
14. Weinberger M. Sodium and blood pressure 2003. Curr Opin Cardiol 2004; 19: 353-6.
15. Katori M, Majima M. A missing link between a high salt intake and blood pressure increase. J Pharmacol Sci 2006; 100: 370- 90.
16. Katori M, Majima M. The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit Review Clin Lab Sci 2003; 40: 43-115.
17. Yuan G, Deng J, Wang T, Zhao C, Xu X, Wang P, et al. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/ protein kinase B and adenosine 5' -monophosphate-activated protein kinase signaling pathways. Endocrinology 2007; 148: 2016-26.
18. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-32.
19. Auricchio A, Hildinger M, Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a singlestep gravity-flow column. Hum Gene Ther 2001; 12: 71-6.
20. Wang C, Dobrzynski E, Chao J, Chao L. Adrenomedullin gene del ivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2001; 280: F964-F971.
21. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensinconverting- enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-92.
22. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-8.
23. Squire IB, O'Kane KP, Anderson N, Reid JL. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 2000; 36: 132-6.
24. El-Dahr SS, Dipp S, Meleg-Smith S, Pinna-Parpaglia P, Madeddu P. Fetal ontogeny and role of metanephr ic bradykinin B2 receptors. Pediatr Nephrol 2000; 14: 288-96.
25. Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 1997; 29: 483-7.
26. Bönner T, Thieven B, Rütten H, Chrosch R, Krone W. Renal kallikrein is a determinant of salt sensitivity. J Hypertens 1993; 11 Suppl 5: S210-211.